By Padmanabhan Ananthan Aug 26 (Reuters) – The U.S. FDA has approved Revolution Medicines' groundbreaking pancreatic cancer drug after it was shown to double the survival rate of patients with
(The article has been published through a syndicated feed. Except for the headline, the content has been published verbatim. Liability lies with original publisher.)
Nvidia forecasts quarterly revenue above estimates
Aug 26 (Reuters) - Nvidia forecast quarterly revenue above Wall Street estimates on Wednesday, but…
Nvidia forecasts quarterly revenue above estimates
Aug 26 (Reuters) - Nvidia forecast quarterly revenue above Wall Street estimates on Wednesday, a…
Briton Brennan takes second Vuelta stage win, Pogacar in control
VIDEO SHOWS: HIGHLIGHTS OF STAGE FIVE OF VUELTA A ESPANA - A 173.4 KM (HILLY)…
